← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 11 · newest first

501. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.The Journal of Immunology · 1989
502. Renal Toxicity of Interleukin-2 Administration in Patients With Metastatic Renal Cell Cancer: Effect of Pre-therapy NephrectomyThe Journal of Urology · 1989
503. Cardiorespiratory effects of immunotherapy with interleukin-2.Journal of Clinical Oncology · 1989
504. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine · 1988
505. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.Journal of Clinical Oncology · 1988
506. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.The Journal of Experimental Medicine · 1988
507. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.Journal of Clinical Oncology · 1988
508. The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2Annals of Surgery · 1988
509. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierJournal of neurosurgery · 1988
510. New Approaches to the Immunotherapy of Cancer Using Interleukin-2Annals of Internal Medicine · 1988
511. Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in MiceJNCI Journal of the National Cancer Institute · 1988
512. The Immunologic Treatment Of CancerCA A Cancer Journal for Clinicians · 1988
513. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.The Journal of Immunology · 1988
514. Technical aspects of lymphokine‐activated killer cell productionJournal of Clinical Apheresis · 1988
515. Anti-Tumor Reactivity of Human Lymphokine Activated Killer (LAK) Cells Against Fresh and Cultured Preparations of Renal Cell CancerThe Journal of Urology · 1988
516. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.The Journal of Experimental Medicine · 1987
517. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.The Journal of Immunology · 1987
518. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.The Journal of Immunology · 1987
519. High-Dose Oral and Intravenous Metoclopramide in Doxorubicin/Cyclophosphamide-Induced Emesis A Randomized Double-Blind StudyAmerican Journal of Clinical Oncology · 1987
520. A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine · 1987
521. Magnetic Resonance Imaging Versus Computed Tomography in the Evaluation of Soft Tissue Tumors of the ExtremitiesAnnals of Surgery · 1987
522. Different Specificities of Cloned T Cells Assessed by in Vitro Proliferation Assays and by the Ability to Mediate Skin Graft Rejection in VivoTransplantation · 1987
523. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.The Journal of Immunology · 1987
524. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.The Journal of Immunology · 1987
525. Clinical effects and toxicity of interleukin-2 in patients with cancerCancer · 1986
526. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience · 1986
527. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology · 1986
528. High-grade soft tissue sarcomas of the extremitiesCancer · 1986
529. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.The Journal of Immunology · 1986
530. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.The Journal of Immunology · 1986
531. Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology · 1986
532. A Novel Approach to the Generation and Identification of Experimental Hepatic Metastases in a Murine ModelJNCI Journal of the National Cancer Institute · 1986
533. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine · 1985
534. Nasogastric Tube Perforation of the NasopharynxSouthern Medical Journal · 1985
535. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.The Journal of Immunology · 1985
536. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.The Journal of Immunology · 1985
537. Lymphokine-activated killer cells: A new approach to immunotherapy of cancerJNCI Journal of the National Cancer Institute · 1985
538. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.The Journal of Experimental Medicine · 1985
539. Combined-Modality Therapy of CancerNew England Journal of Medicine · 1985
540. Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities.Journal of Clinical Oncology · 1985
541. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancerCancer · 1985
542. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patientsCancer · 1985
543. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunkCancer · 1985
544. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.The Journal of Immunology · 1985
545. A Large Scale Method of Separating Multiple Lymphokines Secreted by the Murine El-4 ThymomaJournal of Immunopharmacology · 1985
546. Malignancies in the AIds Patient: Natural History, Treatment Strategies, and Preliminary ResultsAnnals of the New York Academy of Sciences · 1984
547. Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas.The Journal of Immunology · 1984
548. Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science · 1984
549. Blocking by Cyclosporine of Antigen-Induced Maturation and Lymphokine Secretion by Cytotoxic T Lymphocyte HybridomasTransplantation · 1984
550. Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience · 1984